Evidence map›Paper›PMID 29454793›Full record

ArticleGastroenterology2018

P300 Acetyltransferase Mediates Stiffness-Induced Activation of Hepatic Stellate Cells Into Tumor-Promoting Myofibroblasts.

Changwei Dou, Zhikui Liu, Kangsheng Tu, Hongbin Zhang, Chen Chen, Usman Yaqoob, Yuanguo Wang, Jialing Wen, Jan van Deursen, Delphine Sicard and 6 more

Open access · greenAbstract read
In one paragraph

Article in Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 147 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed, 1 pooled it
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

147 citing papers in PubMed, 1 synthesis or guideline pooled it, 231 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

87 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Changwei DouGI Research Unit and Cancer Cell Biology Program, Mayo Clinic, Rochester, Minnesota; Department of Hepatobiliary Surgery, 1st Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Department of Hepatobiliary Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.
Zhikui LiuGI Research Unit and Cancer Cell Biology Program, Mayo Clinic, Rochester, Minnesota; Department of Hepatobiliary Surgery, 1st Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Kangsheng TuDepartment of Hepatobiliary Surgery, 1st Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Tumor Microenvironment and Metastasis, Hormel Institute, University of Minnesota, Minneapolis, Minnesota.
Hongbin ZhangTumor Microenvironment and Metastasis, Hormel Institute, University of Minnesota, Minneapolis, Minnesota.
Chen ChenTumor Microenvironment and Metastasis, Hormel Institute, University of Minnesota, Minneapolis, Minnesota.
Usman YaqoobGI Research Unit and Cancer Cell Biology Program, Mayo Clinic, Rochester, Minnesota.
Yuanguo WangTumor Microenvironment and Metastasis, Hormel Institute, University of Minnesota, Minneapolis, Minnesota.
Jialing WenTumor Microenvironment and Metastasis, Hormel Institute, University of Minnesota, Minneapolis, Minnesota.
Jan van DeursenDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota.
Delphine SicardDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.
Daniel TschumperlinDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.
Hongzhi ZouGuangdong Institute of Gastroenterology, 6th Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Wei-Chien HuangGraduate Institute of Biomedical Science, China Medical University, Taiwan, R.O.C.
Raul UrrutiaGI Research Unit and Cancer Cell Biology Program, Mayo Clinic, Rochester, Minnesota.
Vijay H ShahGI Research Unit and Cancer Cell Biology Program, Mayo Clinic, Rochester, Minnesota. Electronic address: Shah.Vijay@Mayo.edu.
Ningling KangTumor Microenvironment and Metastasis, Hormel Institute, University of Minnesota, Minneapolis, Minnesota. Electronic address: nkang@hi.umn.edu.
Mayo Clinic · USUniversity of Minnesota · USChina Medical University · TWSun Yat-sen University · CN

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
ZINC FINGER GENES AND PANCREATIC CELL GROWTHR01DK052913 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI LOMBERK, GWEN, URRUTIA, RAUL A. · 1998 to 2023
$7.0M
HEPATIC STELLATE CELL REGULATION OF METASTATIC GROWTH IN THE LIVERR01CA160069 · NCI · UNIVERSITY OF MINNESOTA · PI NINGLING KANG · 2011 to 2026
$5.2M
Targeting matrix stiffness in lung and liver fibrosisR01HL133320 · NHLBI · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H., TSCHUMPERLIN, DANIEL J. · 2016 to 2019
$2.2M
NCI NIH HHS R01 CA160069NHLBI NIH HHS R01 HL133320NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK052913
6 · The paper itself

Abstract

BACKGROUND &

aimsHepatic stellate cells (HSCs) contribute to desmoplasia and stiffness of liver metastases by differentiating into matrix-producing myofibroblasts. We investigated whether stiffness due to the presence of tumors increases activation of HSCs into myofibroblasts and their tumor-promoting effects, as well as the role of E1A binding protein p300, a histone acetyltransferase that regulates transcription, in these processes.

methodsHSCs were isolated from liver tissues of patients, mice in which the p300 gene was flanked by 2 loxP sites (p300F/F mice), and p300+/+ mice (controls). The HSCs were placed on polyacrylamide gels with precisely defined stiffness, and their activation (differentiation into myofibroblasts) was assessed by immunofluorescence and immunoblot analyses for alpha-smooth muscle actin. In HSCs from mice, the p300 gene was disrupted by cre recombinase. In human HSCs, levels of p300 were knocked down with small hairpin RNAs or a mutant form of p300 that is not phosphorylated by AKT (p300S1834A) was overexpressed. Human HSCs were also cultured with inhibitors of p300 (C646), PI3K signaling to AKT (LY294002), or RHOA (C3 transferase) and effects on stiffness-induced activation were measured. RNA sequencing and chromatin immunoprecipitation-quantitative polymerase chain reaction were used to identify HSC genes that changed expression levels in response to stiffness. We measured effects of HSC-conditioned media on proliferation of HT29 colon cancer cells and growth of tumors following subcutaneous injection of these cells into mice. MC38 colon cancer cells were injected into portal veins of p300F/Fcre and control mice, and liver metastases were measured. p300F/Fcre and control mice were given intraperitoneal injections of CCl

resultsSubstrate stiffness was sufficient to activate HSCs, leading to nuclear accumulation of p300. Disrupting p300 level or activity blocked stiffness-induced activation of HSCs. In HSCs, substrate stiffness activated AKT signaling via RHOA to induce phosphorylation of p300 at serine 1834; this caused p300 to translocate to the nucleus, where it up-regulated transcription of genes that increase activation of HSCs and metastasis, including CXCL12. MC38 cells, injected into portal veins, formed fewer metastases in livers of p300F/Fcre mice than control mice. Expression of p300 was increased in livers of mice following injection of CCl4; HSC activation and collagen deposition were reduced in livers of p300F/Fcre mice compared with control mice.

conclusionsIn studies of mice, we found liver stiffness to activate HSC differentiation into myofibroblasts, which required nuclear accumulation of p300. p300 increases HSC expression of genes that promote metastasis.

Indexed as

AnimalsBenzoatesCarbon TetrachlorideCarcinoma, HepatocellularCell NucleusCell TransdifferentiationCell Transformation, NeoplasticE1A-Associated p300 ProteinGene Expression ProfilingGene Knockdown TechniquesHepatic Stellate CellsHT29 CellsHumansLiverLiver CirrhosisLiver Neoplasms4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acidBenzoatesCarbon TetrachlorideE1A-Associated p300 ProteinEP300 protein, humanEp300 protein, mouseNitrobenzenesPyrazolesPyrazolonesrhoA GTP-Binding ProteinRHOA protein, humanRNA, Small InterferingChromatin RemodelingEpigenetic ModificationMechanotransductionTumor Progression

Identifiers

PMID29454793
PMCPMC6039101
OpenAlexW2785571650

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.